GW Pharmaceuticals PLC- ADR (GWPH) was Initiated by Cantor Fitzgerald to “Buy” and the brokerage firm has set the Price Target at $181. Cantor Fitzgerald advised their investors in a research report released on Jun 3, 2016.
On the company’s financial health, GW Pharmaceuticals PLC- ADR reported $-0.064 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.09. The company had revenue of $2.65 million for the quarter, compared to analysts expectations of $3.80 million. The company’s revenue was down -58.3 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.03 EPS.
GW Pharmaceuticals PLC- ADR opened for trading at $89.6 and hit $92.94 on the upside on Wednesday, eventually ending the session at $92.17, with a gain of 3.42% or 3.05 points. The heightened volatility saw the trading volume jump to 4,41,935 shares. Company has a market cap of $2,006 M.
GW Pharmaceuticals plc is a United Kingdom-based biopharmaceutical company. The Company is engaged developing a portfolio of cannabinoid medicines including Sativex for the treatment of multiple sclerosis spasticity and cancer pain and Epidiolex for the treatment of childhood epilepsy. The Company also engaged in developing cannabinoids medicines containing controlled substances as well as plant-based prescription pharmaceutical products. The Companys product Sativex is approved in 27 countries and is used as a treatment for symptom improvement in patients with moderate to severe spasticity due to multiple sclerosis (MS). The Sativex is also in Phase III clinical development for the treatment of cancer pain the indication for the United States market.